Education
About Us
Working with TipRanks
Follow Us
Vericel Corp (VCEL)
NASDAQ:VCEL
VCEL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$39.12 - $63.00
Previous CloseN/A
Volume83.17K
Average Volume (3M)427.37K
Market Cap
$2.40B
Enterprise Value$2.84B
Total Cash (Recent Filing)$74.52M
Total Debt (Recent Filing)$98.85M
Price to Earnings (P/E)251.5
Beta1.48
Next Earnings
May 07, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.18
Shares Outstanding50,135,864
10 Day Avg. Volume416,351
30 Day Avg. Volume427,372
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.74
Price to Cash Flow (P/CF)26.00
P/FCF Ratio25.90
Enterprise Value/Market Cap1.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit16.50
Enterprise Value/Ebitda170.79
Forecast
1Y Price Target
$63.86Price Target Upside37.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Vericel News
PremiumCompany Announcements
Vericel Corporation’s 2024 Earnings Call Highlights Growth
PremiumCompany Announcements
Vericel Corporation Reports Strong 2024 Financial Growth
---
Bulls Say, Bears Say
Bulls Say
MACI Arthro AdoptionStrong interest from the physician community for MACI Arthro, with over 250 surgeons having undergone training to date.
NexoBrid Hospital OrdersHospital orders for NexoBrid increased by 42% in 4Q24 compared to the prior quarter, which could be a leading indicator of growth in NexoBrid adoption.
Profitability And Margin GrowthVCEL is also stepping on the gas in terms of profitability, with 2025 EBITDA margins slated to be between 25% and 26%, reflecting the company's strong P&L.
Bears Say
Burn Care Franchise PerformanceVCEL's Burn Care franchise continues to be a source of variability to VCEL's quarterly performance, partially responsible for soft sales guidance.
Epicel And NexoBrid Sales PerformanceEpicel and NexoBrid sales came short of expectations at $6.1M (-22.1%) and $1.0M respectively.
Epicel Revenue DeclineThe decline in 4Q24 Epicel related revenues was attributed to a lower number of patient treatments due to patient health issues as well as fewer grafts per patient.
---
Ownership Overview
0.89% Insiders
35.38% Mutual Funds
0.79% Other Institutional Investors
40.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VCEL FAQ
What was Vericel Corp’s price range in the past 12 months?
Vericel Corp lowest stock price was $39.12 and its highest was $63.00 in the past 12 months.
What is Vericel Corp’s market cap?
Vericel Corp’s market cap is $2.40B.
When is Vericel Corp’s upcoming earnings report date?
Vericel Corp’s upcoming earnings report date is May 07, 2025 which is in 40 days.
How were Vericel Corp’s earnings last quarter?
Vericel Corp released its earnings results on Feb 27, 2025. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.06.
Is Vericel Corp overvalued?
According to Wall Street analysts Vericel Corp’s price is currently Undervalued.
Does Vericel Corp pay dividends?
Vericel Corp does not currently pay dividends.
What is Vericel Corp’s EPS estimate?
Vericel Corp’s EPS estimate is -0.13.
How many shares outstanding does Vericel Corp have?
Vericel Corp has 50,135,864 shares outstanding.
What happened to Vericel Corp’s price movement after its last earnings report?
Vericel Corp reported an EPS of $0.38 in its last earnings report, beating expectations of $0.32. Following the earnings report the stock price went down -6.112%.
Which hedge fund is a major shareholder of Vericel Corp?
Currently, no hedge funds are holding shares in VCEL
---
Vericel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$63.86 (37.57% Upside)
$63.86 (37.57% Upside)
Blogger Sentiment
Bullish
VCEL Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 23.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $152.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.33%
12-Months-Change
Fundamentals
Return on Equity
4.00%
Trailing 12-Months
Asset Growth
22.36%
Trailing 12-Months
Company Description
Vericel Corp
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
---
VCEL Company Deck
---
VCEL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Vericel Corporation reported a strong financial year in 2024 with significant revenue and profitability growth, particularly in the MACI and Burn Care franchises. The launch of MACI Arthro showed promising early indicators. However, challenges such as variability in Epicel's quarterly revenue and increased operating expenses were noted. Despite these challenges, the positive aspects significantly outweigh the lowlights.Read More>---
VCEL Stock 12 Month Forecast
Average Price Target
$63.86
▲(37.57% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Apyx Medical
―
Sarepta Therapeutics
―
MiMedx Group
―
Organogenesis Holdings
―
Best Analysts Covering VCEL
1 Year
1 Year Success Rate
10/15 ratings generated profit
1 Year Average Return
+23.48%
reiterated a buy rating 28 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +23.48% per trade.
---